|
Resolution: standard / high Figure 1.
Effects of the allosteric inhibitor (GNF-2) and Abl kinase inhibitor (Dasatinib) on
Ba/F3 cells expressing unmutated BCR/ABL. (A) XTT assay using Ba/F3 cells expressing empty vector upon exposure to 0.3, 0.6, 1.25,
2.5 and 5 μM GNF-2 and 0.3, 0.6, 1.25, 2.5 and 5 μM Dasatinib. (B) XTT assay using Ba/F3 cells expressing BCR/ABL upon exposure to 0.1, 0.2 and 0.4 μM
GNF-2 and 5, 10, 25, 50 and 100 nM Dasatinib. Proliferation status was determined
by the metabolic activity of cells given by the reduction rate of XTT to formazan.
The means +/- SD of triplicates from one representative experiment out of three performed
are given.
Mian et al. BMC Cancer 2012 12:411 doi:10.1186/1471-2407-12-411 |